Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes. - Wikidata - wikimedia - TriplyDB

Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes.

Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes.

http://www.wikidata.org/entity/Q33389465

about

Safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndrome Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials Molecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted Therapy Comorbidity polypharmacy score and its clinical utility: A pragmatic practitioner's perspective Spotlight on decitabine for myelodysplastic syndromes in Chinese patients New ways to use DNA methyltransferase inhibitors for the treatment of myelodysplastic syndrome 5-azacitidine efficacy and safety in patients aged >65 years with myelodysplastic syndromes outside clinical trials.Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: a retrospective multicenter study.Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher-risk myelodysplastic syndromes.Proteomic Analysis Reveals Autophagy as Pro-Survival Pathway Elicited by Long-Term Exposure with 5-Azacitidine in High-Risk Myelodysplasia.Azacitidine: a review of its use in the management of myelodysplastic syndromes/acute myeloid leukaemia.5-azacytidine in chronic myelomonocytic leukemia: case report and review of literature.Serum microRNA-21 as a potential biomarker for response to hypomethylating agents in myelodysplastic syndromes How much? How frequent? How long? A clinical guide to new therapies in myelodysplastic syndromes International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.Incidence and Burden of the Myelodysplastic Syndromes.The challenge of individualised risk assessment and therapy planning in elderly high-risk myelodysplastic syndromes (MDS) patients.The impact of hypomethylating agents on the cost of care and survival of elderly patients with myelodysplastic syndromes Azacitidine in the management of patients with myelodysplastic syndromes.Managing myelodysplastic syndromes in very old patients: a teaching case report.Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes.Azacitidine might be beneficial in a subgroup of older AML patients compared to intensive chemotherapy: a single centre retrospective study of 227 consecutive patients.Treatment of acute myeloid leukemia with 20-30% bone marrow blasts.Optimizing outcomes with azacitidine: recommendations from Canadian centres of excellence.Treatment of myelodysplastic syndromes in elderly patients.The role of hypomethylating agents in myelodysplastic syndrome: changing the management paradigm.Novel therapeutic strategies using hypomethylating agents in the treatment of myelodysplastic syndrome.Acute myeloid leukemia and myelodysplastic syndromes in older adults.Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes.Azacitidine: A Review in Myelodysplastic Syndromes and Acute Myeloid Leukaemia.Efficacy, safety, and pharmacokinetics of subcutaneous azacitidine in Taiwanese patients with higher-risk myelodysplastic syndromes.Safety and efficacy of azacitidine in elderly patients with intermediate to high-risk myelodysplastic syndromes.Myelodysplastic Syndromes in the Elderly: Treatment Options and Personalized Management.Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study.Results of treatment with azacitidine in patients aged ≥ 75 years included in the Spanish Registry of Myelodysplastic Syndromes.The impact of age on the diagnosis and therapy of myelodysplastic syndromes: results from a retrospective multicenter analysis in Germany.Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia.Complete remission after a single cycle of azacitidine in a case of relapsed acute myeloid leukemia.Azacitidine as salvage therapy in elderly patients with relapsed acute myeloid leukemia after autologous transplantation.Azacytidine for the treatment of myelodysplastic syndromes in the elderly.

P2860

Q24632949-00260050-359D-4009-BCB8-5444BABA56BB Q26745731-EF8211BA-3748-4913-8C81-23CA4987ED05 Q26749870-883444A1-86EE-4378-90E9-9D2275F7D30C Q26775957-1A586B4C-4B9D-48D4-8768-25AA813D437F Q26778454-B85B0370-D033-45A6-BF8C-E0DCF32025CD Q26829132-B20EBD6B-F2C5-4A8B-B5DD-FF010960C1D6 Q33399357-03770B76-A788-4B8B-AE95-BB456EE69FB0 Q33405470-018085B7-3E09-4872-9141-7141DD083C30 Q33412937-BB1E11B4-2116-47AA-9BA8-2A7DBC1D3700 Q33603472-B650849D-AFC2-4769-9212-54C72F6F5F86 Q34273735-52F355FE-56A4-46A3-BA2E-D1728D66ECAA Q35010676-77DD4E71-B495-49F3-A6FD-6BBC938BAE5B Q35087659-6CAB3D05-F19F-4654-B59A-C6A138B68ACF Q35202854-D7165CA0-82E0-47C1-A84A-60CDF871B365 Q35859212-3D592FE5-032A-4131-9B10-6EF95842F3C9 Q36006077-8F2A571C-58D5-45E6-97E0-965D20735144 Q36138278-E26595E1-5FCE-4F6E-9935-D2FA53DCF1E0 Q36280941-2CD428B2-07F2-4D47-8F1B-73C1E5678991 Q36768610-310112D4-3203-49E8-8137-71FFBCD19F01 Q36772626-0EF1F6A0-E8A4-4CDB-91F8-867582054400 Q36799188-632B5004-9F97-4DBF-BD5C-FF79790ACECE Q36805563-BA09F472-49D0-4E0C-A94A-23EF8C8987BD Q36934199-9895ABBB-6C1B-4A9C-8699-03E621DD1CBA Q37577651-217FBBA6-329F-4751-83B5-FAEED7B001A2 Q37856829-1DDE47CF-B04C-4E03-A5FF-440C2863E8A0 Q38160051-356064E1-EC7B-485F-887C-507C6474C5CB Q38172875-B2CB47A5-C3F1-4377-8988-EC2F435C6624 Q38234863-3E274644-C456-4408-9F0D-A4F2656D0985 Q38455680-86CC9D89-2D3C-4BF1-9624-F1A3C1BADBF0 Q38837834-1B688FAC-FC57-4436-88E6-C1C36B2501EE Q38998074-B7262DD8-6C09-420A-BDBB-E906F4B0650D Q39064474-CE97A7AF-8397-4E8A-895B-11C3B644ACE2 Q40420210-FB8BF79D-6E45-49A2-AD79-3C62F54699CE Q43134067-631EBDAF-5EB2-4A74-8F3D-2B262875ED91 Q43558574-574DBBBF-7FF0-4267-9D07-1DDDD8E30521 Q44895438-AC576CE0-4F27-40CC-ABC6-99EECE1BFF8F Q44951134-8DBCBF4F-FC16-4799-8551-4E2CD993E173 Q45221235-4902E5B4-46EF-45DC-9B12-DB9C8FEAD707 Q45656971-8353BF69-EAF0-446D-8DD2-450B754DCBFA Q46606966-F3543F70-64DF-449B-83F1-858C14570330

P2860

Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes.

http://www.wikidata.org/entity/Q33389465

description

2010 nî lūn-bûn

@nan

2010 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Effects of azacitidine compare ...... isk myelodysplastic syndromes.

@ast

Effects of azacitidine compare ...... isk myelodysplastic syndromes.

@en

type

label

Effects of azacitidine compare ...... isk myelodysplastic syndromes.

@ast

Effects of azacitidine compare ...... isk myelodysplastic syndromes.

@en

prefLabel

Effects of azacitidine compare ...... isk myelodysplastic syndromes.

@ast

Effects of azacitidine compare ...... isk myelodysplastic syndromes.

@en

P1433

Q33389465-D961954A-1602-48B7-9CAD-0A50BB0685F0

P1476

Q33389465-D478CC57-78C7-4498-8F89-9A6E5C203352

P2093

Q33389465-14E6A0AB-2A9B-49E0-8E4C-DDB520FBA238

Q33389465-35F1244A-7EC3-42A9-BBD8-890ECD093CE0

Q33389465-45A72EAD-88D2-4392-BAC6-7D90B57BC8B6

Q33389465-5F22310D-1C27-45D0-863F-C25C0F825FED

Q33389465-6FE0CD6A-499F-474B-933D-69B4D8C21743

Q33389465-AC08D498-F32F-4F81-A22E-C3E53A10543D

Q33389465-C0D8CA8B-4ADC-45DB-AA79-5C99F5FBC202

Q33389465-CC548B8C-C357-4EF0-9A46-A838C2E48EAA

Q33389465-D6118EE6-0578-4D64-B477-482C19949E5D

P2860

Q33389465-07FC745D-77F1-4A81-8B18-F1B4DAD6D7A9

Q33389465-0B03B33F-86C0-4854-ADD7-9F8228C15F71

Q33389465-247A0444-05BC-4BDB-A096-14A29540682B

Q33389465-31EFA294-9DEA-437B-8DF0-86258A080F09

Q33389465-38AFC058-037D-4CF8-A845-546D3F2F941D

Q33389465-4F4153EA-9CA7-4B79-8031-B8129AB4FC0D

Q33389465-4F7E208F-7065-4D1D-92EF-227497D7C865

Q33389465-60357BB8-EC32-493D-B87B-32C278500415

Q33389465-7171DEF8-D2F1-477C-A32F-6C6BAFAF8AF7

Q33389465-9CD50E42-ECD9-4359-A4EE-6F3D0FEF2B71

P304

Q33389465-E5C22701-1891-4339-92C5-7BF82D414A2E

P31

Q33389465-11E4C80C-8F12-48C8-8C71-434A5DEC6C05

P356

Q33389465-8ECC8333-A217-4A05-9DAB-F4498676A5A7

P433

Q33389465-4127E311-78EB-4272-91ED-E45C6D774AD2

P478

Q33389465-9D70BF04-E290-4EC5-90FF-40487152B94F

P50

Q33389465-1BFBA1BB-97D5-473B-A8BF-CACB49C17499

Q33389465-2E6F8830-0D56-4E4D-92DC-9FFB1C037678

Q33389465-A0DC2FD0-4489-486F-85FE-51BA5B27AAD0

P577

Q33389465-24463BA6-1892-43C0-ADE3-A09B1AEC3D02

P698

Q33389465-780CCA33-027D-4E8E-9114-31FCA0523F0B

P932

Q33389465-90D768FB-2834-4C4F-839A-847A9E07E3A6

P356

J.CRITREVONC.2010.04.005

P1433

Critical Reviews in Oncology Hematology

P1476

Effects of azacitidine compare ...... isk myelodysplastic syndromes.

@en

P2093

Alan F List

http://www.w3.org/2001/XMLSchema#string

C L Beach

http://www.w3.org/2001/XMLSchema#string

David McKenzie

http://www.w3.org/2001/XMLSchema#string

Eva Hellström-Lindberg

http://www.w3.org/2001/XMLSchema#string

Ghulam J Mufti

http://www.w3.org/2001/XMLSchema#string

Jay Backstrom

http://www.w3.org/2001/XMLSchema#string

John F Seymour

http://www.w3.org/2001/XMLSchema#string

Lewis R Silverman

http://www.w3.org/2001/XMLSchema#string

Steven D Gore

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

International scoring system for evaluating prognosis in myelodysplastic syndromes

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.

The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase-III intergroup study.

Low dose Ara-C for myelodysplastic syndromes: is it still a current therapy?

Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approaches.

Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys.

Arsenic and old lace: novel approaches in elderly patients with acute myeloid leukemia.

Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*.

P304

218-227

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CRITREVONC.2010.04.005

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

76

http://www.w3.org/2001/XMLSchema#string

P50

Eva Hellström-Lindberg

Valeria Santini

P577

2010-05-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20451404

http://www.w3.org/2001/XMLSchema#string

P932

4000027

http://www.w3.org/2001/XMLSchema#string